Inhaled Cannabis for Treatment of PTSD

Part of paid clinical trials in Cave Creek, Arizona.

Sponsor
Multidisciplinary Association for Psychedelic Studies
Study ID
NCT07224698
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Post Traumatic Stress Disorder PTSD

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • High THC Cannabis — DRUG
    dried flower of the Cannabis sativa or indica plant with high (18-22%) THC content
  • Placebo cannabis — DRUG
    Placebo contains \<1% THC

Study Details

The rationale for the use of inhalational cannabis to potentially treat PTSD symptoms is based on the many reports of cannabis attenuating PTSD symptom expression among individuals with PTSD, including veterans. Study MJP2 is intended to build off MJP-1 through use of a larger sample size, a parallel study design, and subjective bias mitigation methods to re-examine the use of inhaled high THC-containing cannabis versus placebo for management of PTSD symptoms in a U.S. Veteran sample. Together these studies are intended to provide valuable insights on the already widespread use of cannabis in individuals with PTSD, for which there is currently a lack of controlled evidence available reflective of this real-world use.

Key Dates

Start date
Feb 1, 2026
Status verified
Dec 2025
Primary completion
Jun 30, 2027
Completion
Nov 30, 2027

Study Design

Enrollment
320 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Active Treatment
  • Placebo Comparator: Placebo

Primary Outcome Measure

Efficacy: Compare changes in PTSD symptom severity in the high THC vs placebo cannabis group as measured by Clinician Administered PTSD Scale for DSM-5, Revised (CAPS-5-R). [ Time Frame: Intro 1 (Day 1), End of Treatment (Day 35) ]

Locations (1)

FacilityCityStateZIPSite coordinators
Scottsdale Research InstituteCave CreekArizona85331
Principal Investigator
[email protected]
480-326-6023
Sue Sisley, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Cave Creek, AZ

By research site
Scottsdale Research Institute· Cave Creek, AZ

Related Studies